Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
Gene Therapy
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Sanofi (NASDAQ: SNY) has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics.
“We are pleased to advance our ongoing in vivo collaboration with Sanofi to address a second therapeutic target based on our progress to date working on potentially curative genetic medicines,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe. “Our teams have built a strong foundation combining Scribe’s engineered CRISPR technologies with Sanofi’s capabilities in genomic medicine. Together, we are dedicated to achieving our common goal of bringing breakthrough in vivo genetic medicines to patients in need.”
CRISPR by Design™, Scribe’s data-driven design and engineering approach for optimizing its CRISPR-based platforms and assets including X-Editing (XE) technologies, continues to drive forward a new era of truly transformative genetic medicines. Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.
About Scribe Therapeutics
Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.